FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1708007155> ?p ?o ?g. }

• W1708007155 endingPage "452" @default.
• W1708007155 startingPage "445" @default.
• W1708007155 abstract "Abstract Background and objective Treatment with pirfenidone may slow the decline in vital capacity and increase progression‐free survival ( PFS ) in idiopathic pulmonary fibrosis ( IPF ). The effects of combination therapy with inhaled N ‐acetylcysteine ( NAC ) and pirfenidone are unclear. We assessed the effects of this combination therapy in patients with advanced IPF . Methods Patients with a diagnosis of advanced IPF ( J apanese R espiratory S ociety stage III/IV IPF ) and a relative decline in forced vital capacity ( FVC ) of ≥10% within the previous 6 (±2) months were enrolled. Outcomes were evaluated in a 12‐month follow‐up pulmonary function test. Treatment was considered ineffective if the decline in FVC was ≥10% and effective if the decline was <10%. We compared clinical characteristics, effectiveness and PFS between patients receiving inhaled NAC plus pirfenidone ( n = 24) and those receiving pirfenidone alone (control; n = 10). Results Data from 34 IPF patients (age range, 59–82 years) were analysed. At the 12‐month follow‐up examination, treatment was deemed effective in 8 of 17 (47%) patients receiving NAC plus pirfenidone and in 2 of 10 (20%) receiving pirfenidone alone. The annual rate of change in FVC was −610 mL in the NAC plus pirfenidone group and −1320 mL in the pirfenidone group ( P < 0.01). PFS was longer (304 days) in the NAC plus pirfenidone group than in the pirfenidone group (168 days; P = 0.016). Conclusions Combination treatment with inhaled NAC and oral pirfenidone reduced the rate of annual FVC decline and improved PFS in patients with advanced IPF ." @default.
• W1708007155 created "2016-06-24" @default.
• W1708007155 creator A5001988339 @default.
• W1708007155 creator A5031048743 @default.
• W1708007155 creator A5036317882 @default.
• W1708007155 creator A5052933025 @default.
• W1708007155 creator A5062611521 @default.
• W1708007155 creator A5065567396 @default.
• W1708007155 creator A5080290598 @default.
• W1708007155 creator A5081154682 @default.
• W1708007155 creator A5082735665 @default.
• W1708007155 creator A5063242382 @default.
• W1708007155 date "2015-02-02" @default.
• W1708007155 modified "2023-10-18" @default.
• W1708007155 title "Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: A case-control study" @default.
• W1708007155 cites W1569431722 @default.
• W1708007155 cites W1853423207 @default.
• W1708007155 cites W1957975414 @default.
• W1708007155 cites W1971419861 @default.
• W1708007155 cites W2018381516 @default.
• W1708007155 cites W2024770617 @default.
• W1708007155 cites W2057292199 @default.
• W1708007155 cites W2063195524 @default.
• W1708007155 cites W2063902734 @default.
• W1708007155 cites W2078164553 @default.
• W1708007155 cites W2085604666 @default.
• W1708007155 cites W2096828977 @default.
• W1708007155 cites W2097001214 @default.
• W1708007155 cites W2098305693 @default.
• W1708007155 cites W2108226118 @default.
• W1708007155 cites W2111459732 @default.
• W1708007155 cites W2125322938 @default.
• W1708007155 cites W2131029325 @default.
• W1708007155 cites W2140421916 @default.
• W1708007155 cites W2142941142 @default.
• W1708007155 cites W2144131169 @default.
• W1708007155 cites W2156375589 @default.
• W1708007155 cites W2167383172 @default.
• W1708007155 cites W2168666423 @default.
• W1708007155 cites W4252692455 @default.
• W1708007155 cites W4296612182 @default.
• W1708007155 doi "https://doi.org/10.1111/resp.12477" @default.
• W1708007155 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25639750" @default.
• W1708007155 hasPublicationYear "2015" @default.
• W1708007155 type Work @default.
• W1708007155 sameAs 1708007155 @default.
• W1708007155 citedByCount "42" @default.
• W1708007155 countsByYear W17080071552015 @default.
• W1708007155 countsByYear W17080071552016 @default.
• W1708007155 countsByYear W17080071552017 @default.
• W1708007155 countsByYear W17080071552018 @default.
• W1708007155 countsByYear W17080071552019 @default.
• W1708007155 countsByYear W17080071552020 @default.
• W1708007155 countsByYear W17080071552021 @default.
• W1708007155 countsByYear W17080071552022 @default.
• W1708007155 countsByYear W17080071552023 @default.
• W1708007155 crossrefType "journal-article" @default.
• W1708007155 hasAuthorship W1708007155A5001988339 @default.
• W1708007155 hasAuthorship W1708007155A5031048743 @default.
• W1708007155 hasAuthorship W1708007155A5036317882 @default.
• W1708007155 hasAuthorship W1708007155A5052933025 @default.
• W1708007155 hasAuthorship W1708007155A5062611521 @default.
• W1708007155 hasAuthorship W1708007155A5063242382 @default.
• W1708007155 hasAuthorship W1708007155A5065567396 @default.
• W1708007155 hasAuthorship W1708007155A5080290598 @default.
• W1708007155 hasAuthorship W1708007155A5081154682 @default.
• W1708007155 hasAuthorship W1708007155A5082735665 @default.
• W1708007155 hasConcept C126322002 @default.
• W1708007155 hasConcept C141071460 @default.
• W1708007155 hasConcept C165637977 @default.
• W1708007155 hasConcept C185592680 @default.
• W1708007155 hasConcept C2777714996 @default.
• W1708007155 hasConcept C2777847592 @default.
• W1708007155 hasConcept C2778004101 @default.
• W1708007155 hasConcept C2778341716 @default.
• W1708007155 hasConcept C2779832356 @default.
• W1708007155 hasConcept C3018587741 @default.
• W1708007155 hasConcept C55493867 @default.
• W1708007155 hasConcept C55520419 @default.
• W1708007155 hasConcept C71924100 @default.
• W1708007155 hasConcept C75603125 @default.
• W1708007155 hasConcept C90924648 @default.
• W1708007155 hasConceptScore W1708007155C126322002 @default.
• W1708007155 hasConceptScore W1708007155C141071460 @default.
• W1708007155 hasConceptScore W1708007155C165637977 @default.
• W1708007155 hasConceptScore W1708007155C185592680 @default.
• W1708007155 hasConceptScore W1708007155C2777714996 @default.
• W1708007155 hasConceptScore W1708007155C2777847592 @default.
• W1708007155 hasConceptScore W1708007155C2778004101 @default.
• W1708007155 hasConceptScore W1708007155C2778341716 @default.
• W1708007155 hasConceptScore W1708007155C2779832356 @default.
• W1708007155 hasConceptScore W1708007155C3018587741 @default.
• W1708007155 hasConceptScore W1708007155C55493867 @default.
• W1708007155 hasConceptScore W1708007155C55520419 @default.
• W1708007155 hasConceptScore W1708007155C71924100 @default.
• W1708007155 hasConceptScore W1708007155C75603125 @default.
• W1708007155 hasConceptScore W1708007155C90924648 @default.
• W1708007155 hasIssue "3" @default.

• next